Profile picture for user ltro223

Louis Rodgers

Connect

(859) 218-3854
louis.rodgers@uky.edu
Bauer Lab, 760 Press Ave., 123 HKRB

Positions

  • MD/PhD Student

College Unit(s)

Other Affiliation(s)
  • College of Pharmacy

Biography and Education

Education

CRTA Postbac - NIH/NCI (2015-2017)

B.S. Chemistry - Centre College (2011-2015)

Summary:

Current Year: G5
CRTA Postbac - NIH/NCI (2015-2017); Centre College (2011-2015)
Hometown: Florence, KY

Research

Following his undergraduate education at Centre College, Louis participated in the NIH Postbac CRTA Program under the guidance of Dr. William Figg (clinical pharmacology/genitourinary malignancies) and Dr. Katherine Warren (pediatric neuro-oncology). During his time at the NIH, Louis conducted pharmacokinetic studies in an effort to develop new therapeutic strategies for the treatment of cancers in children with tumors of the central nervous system. With an interest in continuing in the field of neuro-oncology, Louis was thrilled to pursue a career as a physician-scientist at the University of Kentucky because of its strong oncology and neuroscience programs. Currently, Louis is a graduate research assistant in the laboratory of Dr. Bjoern Bauer, studying the overexpression of the drug-efflux pumps, P-gp & BCRP, in glioblastoma and the development of a novel therapeutic strategy to increase brain uptake of anticancer drugs.

Selected Publications

ResearchGate: https://www.researchgate.net/profile/Louis_Rodgers

MyNCBI: https://www.ncbi.nlm.nih.gov/myncbi/1p1VC5v0jfoIk6/bibliography/public/

Schulz JA, Rodgers LT, Kryscio RJ, Hartz AMS, Bauer B. Characterization and Comparison of Human Glioblastoma Models. BMC Cancer. 2022 (IF: 4.430)

Lester McCully C, Rodgers LT, Cruz R, Thomas ML, Peer CJ, Figg WD, Barnard D, Warren KE. Cerebrospinal fluid flow rate and apparent volume in rhesus macaques (Macaca mulatta) as determined by the pharmacokinetics of intrathecally administered inulin. Comp Med. 2020. doi: 10.30802/AALAS-CM-99-990010 (IF: 0.800)

Hipp S, Goldman S, Kaushal A, Krauze A, Citrin D, Glod J, Walker K, Shih JH, Sethumadhavan H, O’Neill K, Garvin JH, Glade-Bender J, Karajannis MA, Atlas MP, Rodgers LT, Peer CJ, Savage J, Camphausen KA, Brunson N, Packer R, Streicher H, Figg WD, Warren KE. A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas or High-Grade Gliomas. J Neurooncol. 2020. doi: 10.1007/s11060-020-03627-0 (IF: 3.267)

Vyas KS, DeCoster RC, Burns JC, Rodgers LT, Shrout MA, Mercer JP, Coquillard C, Dugan AJ, Rinker BD, Vasconez HC. Autologous Fat Grafting Does Not Increase Risk of Oncologic Recurrence in the Reconstructed Breast. Ann Plast Surg. 2020. doi: 10.1097/SAP.0000000000002285 (IF: 1.448)

McCully CM, Rodgers LT, Cruz R, Thomas ML, Peer CJ, Figg WD, Warren KE. Plasma and Cerebrospinal Fluid Pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, Alone and in Combination with Inulin in Non-human Primate CSF Models. Neuro-Oncology Advances. 2020. doi: 10.1093/noajnl/vdaa005

Rodgers LT, McCully CM, Odabas A, Cruz R, Peer CJ, Figg WD, Warren KE. Characterizing the Pharmacokinetics of Panobinostat in a Non-human Primate Model for the Treatment of Diffuse Intrinsic Pontine Glioma. Cancer Chemother Pharmacol. 2020; 85(4): 827-830. doi:10.1007/s00280-019-04021-y (IF: 3.008)

Peer CJ, Jung-Min L, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women’s cancers. Cancer Chemother Pharmacol. 2017; 80(1): 165-175. doi: 10.1007/s00280-017-3346-1 (IF: 2.808)

Rodgers L, Peer CJ, Figg WD. Diagnosis, staging, and risk stratification in prostate cancer: utilizing diagnostic tools to avoid unnecessary therapies and side effects. Cancer Biol Ther. 2017; 18(7): 470-472. doi: 10.1080/15384047.2017.1323600 (IF: 3.373) (Review)

Miyahara H, Yadavilli S, Natsumeda M, Rubens J, Rodgers L, Kambhampati M, Taylor I, Kaur H, Asnaghi L, Eberhart CG, Warren KE, Nazarian J, Raabe EH. The dual mTOR kinase inhibitor TAK 228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett. 2017; 400: 110-116. doi: 10.1016/j.canlet.2017.04.019 (IF: 6.491)

League-Pascual JC, McCully CM, Shandilya S, Ronner L, Rodgers L, Cruz R, Peer CJ, Figg WD, Warren KE. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. J Neurooncol. 2017; 132(3): 401-407. doi: 10.1007/s11060-017-2388-x (IF: 3.060)

Peer CJ, Ronner L, Rodgers L, McCully CM, Warren KE, Figg WD. Quantification of temozolomide in nonhuman primate fluids by isocratic ultra-high performance liquid chromatography-tandem mass spectrometry to study brain tissue penetration following intranasal or intravenous delivery. Separations. 2016; 3(1), 4. doi: 10.3390/chromatography3010004 (IF: 2.690)